SCHEDULE: Goldman Sachs Adjusts Karyopharm Therapeutics Stake

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have updated their beneficial ownership filing for Karyopharm Therapeutics Inc., reporting a 6.3% stake.

Summary

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Karyopharm Therapeutics Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 1,429,197.87 shares of Karyopharm Therapeutics Inc. common stock.
• This represents 6.3% of the class of securities outstanding.
• The filing indicates that Goldman Sachs & Co. LLC is a broker-dealer and investment adviser.
• The filing is an amendment to a previous filing and does not appear to indicate a significant change in strategy or financial performance of Karyopharm Therapeutics Inc. itself, but rather a reporting of ownership by a financial institution.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without new financial or strategic information.

Positives

• The filing confirms continued institutional interest in Karyopharm Therapeutics Inc. through the reporting of a significant stake by a major financial institution.
• The reporting is in compliance with SEC regulations, ensuring transparency for investors.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Karyopharm Therapeutics Inc., making it difficult to assess the company's current operational health.
• The nature of the filing as an amendment to a Schedule 13G suggests a routine update rather than a significant positive development for the company.

Risks

• The filing does not explicitly mention any new risks related to Karyopharm Therapeutics Inc.'s operations or market position.
• The primary risk associated with this type of filing is the potential for future changes in beneficial ownership by large holders, which could impact stock price volatility.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Karyopharm Therapeutics Inc.'s future performance. It solely reports on the beneficial ownership of securities by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate significant holdings. The presence of Goldman Sachs as a holder is typical for publicly traded companies and reflects standard market activity rather than a specific company event.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Creditors: No direct impact indicated, as the filing pertains to equity ownership.
• Employees: No direct impact indicated.
• Customers/Suppliers: No direct impact indicated.

Next Steps

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC will continue to report any changes in their beneficial ownership of Karyopharm Therapeutics Inc. securities as required by SEC regulations.

Key Dates

Keywords

Karyopharm Therapeutics, Schedule 13G, Beneficial Ownership, Goldman Sachs, Common Stock, SEC Filing, Investment Adviser, Broker-Dealer